Cargando…

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

BACKGROUND: Recent studies of advanced lung cancer patients have shown that circulating tumor DNA (ctDNA) analysis is useful for molecular profiling, monitoring tumor burden, and predicting therapeutic efficacies and disease progression. However, the usefulness of ctDNA analysis in surgically resect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohara, Shuta, Suda, Kenichi, Sakai, Kazuko, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Fujino, Toshio, Koga, Takamasa, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653121/ https://www.ncbi.nlm.nih.gov/pubmed/33209612 http://dx.doi.org/10.21037/tlcr-20-505

Ejemplares similares

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
por: Koga, Takamasa, et al.
Publicado: (2023)

Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
por: Ohara, Shuta, et al.
Publicado: (2019)

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
por: Hamada, Akira, et al.
Publicado: (2022)

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
por: Koga, Takamasa, et al.
Publicado: (2021)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
por: Suda, Kenichi, et al.
Publicado: (2019)

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer
por: Mizuuchi, Hiroshi, et al.
Publicado: (2016)

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
por: Sato, Katsuaki, et al.
Publicado: (2016)

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
por: Ohara, Shuta, et al.
Publicado: (2021)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
por: Koga, Takamasa, et al.
Publicado: (2022)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015)

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection
por: Tomizawa, Kenji, et al.
Publicado: (2015)

Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
por: Hamada, Akira, et al.
Publicado: (2023)

Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
por: Suda, Kenichi, et al.
Publicado: (2014)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival
por: Terashima, Masato, et al.
Publicado: (2014)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
por: Suda, Kenichi, et al.
Publicado: (2020)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe
por: Tomizawa, Kenji, et al.
Publicado: (2015)

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens
por: Sakai, Kazuko, et al.
Publicado: (2019)

Surgical therapy for pulmonary metastasis of breast cancer
por: Soh, Junichi, et al.
Publicado: (2020)

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions
por: Sakai, Kazuko, et al.
Publicado: (2014)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
por: Hibi, Masaaki, et al.
Publicado: (2016)

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer
por: Sakai, Kazuko, et al.
Publicado: (2015)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
por: KOGITA, AKIHIRO, et al.
Publicado: (2014)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
por: Togashi, Yosuke, et al.
Publicado: (2014)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jg4imt2gbtpl87i1nktukl042s